Merck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals
We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...
Fintel on MSN7h
Bernstein Initiates Coverage of Merck (MRK) with Market Perform Recommendation
Fintel reports that on October 17, 2024, Bernstein initiated coverage of Merck (NYSE:MRK) with a Market Perform ...
BioSpace10h
Merck, Pfizer Tout Promising Respective Data in RSV With High Rates of Prevention
Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...
STAT11h
Potential competition for RSV prophylactic Beyfortus
New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...
MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win
The company’s monoclonal antibody met primary endpoints in Phase IIb/III trial in infants entering their first respiratory ...
kffhealthnews12h
CVS Ousts CEO Amid Company’s Struggles To Drive Up Profits, Stocks
CVS announced Friday that CEO Karen Lynch will be replaced by David Joyner, as consumer spending drops at the company's retail pharmacies and Aetna, its insurance unit, faces higher medical costs.
Medscape14h
Cendakimab That Targets IL-13 Shows Promise in Eosinophilic Esophagitis
Interim phase 3 results showed the IL-13 monoclonal antibody improves histology and symptoms in EoE, even in participants ...
Why This Pharma Boss Isn’t Chasing the Obesity Hype
Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.
Merck's RSV antibody for infants effective in reducing some types of infections in study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...